2. Search Result
Search Result
Pathways Recommended: Membrane Transporter/Ion Channel
Results for "

brain membrane

" in MedChemExpress (MCE) Product Catalog:

97

Inhibitors & Agonists

3

Screening Libraries

3

Biochemical Assay Reagents

11

Peptides

12

Natural
Products

1

Recombinant Proteins

8

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2326
    (±)-Anatoxin A fumarate

    		nAChR Neurological Disease
    (±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits Ki values of 1.25 nM and 1.84 μM for binding to putative α4β2-type nAChR and α7-type nAChR in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ 3H]-dopamine release from rat striatal synaptosomes (EC50=134 nM) .
    (±)-Anatoxin A fumarate
  • HY-18698
    L-701324

    		iGluR Neurological Disease
    L-701324 is a potent, orally active NMDA receptor antagonist that antagonizes the activity of the NMDA receptor by blocking its glycine B binding site. L-701324 binds with high affinity to rat brain membranes (IC50=2 nM). L-701324 has antidepressant activity .
    L-701324
  • HY-15084
    Dizocilpine maleate
    Maximum Cited Publications
    32 Publications Verification

    (+)-MK 801 Maleate

    		 iGluR Neurological Disease
    Dizocilpine maleate (MK-801 maleate) is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
    Dizocilpine maleate
  • HY-110256
    N-Acetylcysteine amide
    10+ Cited Publications

    		 Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology
    N-Acetylcysteine amide is a cell membranes and blood brain barrier permeant thiol antioxidant and neuroprotective agent, reduces ROS production.
    N-Acetylcysteine amide
  • HY-12332
    JW 642
    2 Publications Verification

    		 MAGL Neurological Disease
    JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.
    JW 642
  • HY-148246
    MU1700

    		TGF-β Receptor Cancer
    MU1700 is an orally active and potent ALK1/2 inhibitor with IC50s of 13 nM and 6 nM, respectively. MU1700 shows cell membrane permeability and high brain permeability .
    MU1700
  • HY-P3883
    [DAla4] Substance P (4-11)

    		Neurokinin Receptor Neurological Disease
    [DAla4] Substance P (4-11) is an analog of Substance P (Substance P (HY-P0201)) that inhibits the binding of 125I-Bolton Hunter-conjugated Eledoisin (Eledoisin (HY-P0006)) (IC50 of 0.5 μM) and 125I-Bolton Hunter-conjugated Substance P (IC50 of 0.15 μM) to rat brain cortex membranes .
    [DAla4] Substance P (4-11)
  • HY-100821
    2,4-Dihydroxyphenylacetylasparagine

    		Bacterial Infection
    2,4-Dihydroxyphenylacetylasparagine is a potent and selective antagonist of glutamate. 2,4-Dihydroxyphenylacetylasparagine inhibits glutamate binding to rat brain synaptic membranes .
    2,4-Dihydroxyphenylacetylasparagine
  • HY-123594
    R-2 Methanandamide

    		Cannabinoid Receptor Neurological Disease
    R-2 Methanandamide (Compound 2) is a cannabinoid Anandamide (HY-10863) analog with a Ki of 119 nM for the cannabinoid receptor (Ki is determined using rat brain membranes with PMSF) .
    R-2 Methanandamide
  • HY-119696S
    MTIC-d3

    		Isotope-Labeled Compounds Drug Metabolite Neurological Disease Cancer
    MTIC-d3 is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ). MITC has lower bioavailability in the brain compared with TMZ, because the agent’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane .
    MTIC-d3
  • HY-B1237A
    Suloctidil hydrochloride

    		Na+/K+ ATPase Cardiovascular Disease
    Suloctidil hydrochloride hydrochloride is an active agent against on Na+/K+ ATPase activity and on membrane fluidity in rat brain synaptosomes. Suloctidil hydrochloride is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders.
    Suloctidil hydrochloride
  • HY-B1237
    Suloctidil

    		Na+/K+ ATPase Cardiovascular Disease
    Suloctidil is a new drug that is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders Target： Effect of suloctidil on Na+/K+ ATPase activity and on membrane fluidity in rat brain synaptosomes.
    Suloctidil
  • HY-106745
    Elziverine

    Ro 22-4839

    		 Calmodulin Cardiovascular Disease
    Elziverine (Ro 22-4839) is a brain circulation improvement agent with vasospasm antispasmodic effects. Elziverine is a calmodulin antagonist. Elziverine inhibits erythrocyte cell membrane rupture, platelet aggregation and lipid peroxidation .
    Elziverine
  • HY-13510R
    Cutamesine dihydrochloride (Standard)

    		Sigma Receptor Neurological Disease
    Cutamesine dihydrochloride (Standard) is the analytical standard of Cutamesine dihydrochloride. This product is intended for research and analytical applications. Cutamesine dihydrochloride (SA4503 dihydrochloride; AGY94806 dihydrochloride) is a potent Sigma 1 receptor agonist with an IC50 of 17.4 nM in guinea pig brain membranes.
    Cutamesine dihydrochloride (Standard)
  • HY-14136
    Rimonabant
    5+ Cited Publications

    SR141716

    		 Cannabinoid Receptor Bacterial Infection Metabolic Disease Cancer
    Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
    Rimonabant
  • HY-160791
    Claramine

    		Phosphatase Infection Cancer
    Claramine is a steroid polyamine with blood-brain barrier permeability. Claramine can regulate the properties of lipid membranes and protect cells from various biological toxins, including misfolded protein oligomers and biological protein-based toxins .
    Claramine
  • HY-13918
    Etimizol

    Ethimizole; Ethymisol; Ethymisole

    		 Potassium Channel Neurological Disease
    Etimizol(Ethymisole; Antiffine; Ethylnorantifein) was shown to relieve amnesia effectively in the origin of which there is the hypoxic component (hypobaric hypoxia, actinomycin D, mechanical injury of the brain). Etimizol can decrease the K- + permeability of neurons' membrane during action potential.
    Etimizol
  • HY-10712
    Org-24598

    		GlyT Neurological Disease
    Org-24598 is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 can inhibit the specific binding of [ 3H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .
    Org-24598
  • HY-106808
    Cerebrocrast

    IOS-1.1212

    		 Calcium Channel Chloride Channel Neurological Disease
    Cerebrocrast (IOS-1.1212) is a 1,4-dihydropyridine (DHP) derivative. Cerebrocrast has a high affinity for the membrane lipid bilayer and it can easily penetrate the blood-brain barrier and incorporate into the plasma and organelle membranes, including those of mitochondria. Cerebrocrast promotes the cotransport of H+ and Cl- in rat liver mitochondria. Cerebrocrast also exhibits neuroprotective and cognition enhancer properties .
    Cerebrocrast
  • HY-100937
    DPCPX
    5+ Cited Publications

    PD 116948

    		 Adenosine Receptor Cardiovascular Disease
    DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a Ki of 0.46 nM in 3H-CHA binding to A1 receptors in rat whole brain membranes .
    DPCPX
  • HY-15249
    JZL 184
    5 Publications Verification

    		 MAGL Neurological Disease
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .
    JZL 184
  • HY-10713
    Org-24598 lithium

    		GlyT Neurological Disease
    Org-24598 lithium is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 lithium can inhibit the specific binding of [ 3H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .
    Org-24598 lithium
  • HY-102064
    SR 57227A
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    SR 57227A is a potent, orally active and selective 5-HT3 receptor agonist, with ability to cross the blood brain barrier. SR 57227A has affinities (IC50) varying between 2.8 and 250 nM for 5-HT3 receptor binding sites in rat cortical membranes and on whole NG 108-15 cells or their membranes. Anti-depressant effects .
    SR 57227A
  • HY-A0160
    Indalpine

    LM 5008

    		 Serotonin Transporter Neurological Disease
    Indalpine (LM 5008) is a potent and selective 5-HT uptake blocker. Indalpine is potent in displacing 3H-5-HT bound to brain membranes with the IC50 of 36 μM . Indalpine, two antidepressant agent .
    Indalpine
  • HY-18236
    MDL-28170
    5+ Cited Publications

    Calpain Inhibitor III

    		 Proteasome Neurological Disease Inflammation/Immunology
    MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration . MDL-28170 also block γ-secretase .
    MDL-28170
  • HY-P10310
    F9170

    		HIV Infection
    F9170 is an amphipathic peptide with an activity of inactivate HIV-1 virions. F9170 targets the conserved cytoplasmic tail of HIV-1 env and disrupts the integrity of the viral membrane. F9170 is able to cross the blood-brain barrier (BBB) .
    F9170
  • HY-59201A
    A-582941 dihydrochloride

    		nAChR 5-HT Receptor Neurological Disease
    A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with Kis of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT3 receptor with a Ki of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research .
    A-582941 dihydrochloride
  • HY-14813
    Cutamesine
    3 Publications Verification

    SA4503; AGY 94806

    		 Sigma Receptor Neurological Disease
    Cutamesine (SA4503) is a potent and selective sigma 1 receptor agonist with an IC50 of 17.4 nM in guinea pig brain membranes. Cutamesine shows >100-fold less affinity for the sigma 2 receptor (IC50 of 1784 nM). Cutamesine has antidepressant effects .
    Cutamesine
  • HY-13510
    Cutamesine dihydrochloride
    3 Publications Verification

    SA4503 dihydrochloride; AGY94806 dihydrochloride

    		 Sigma Receptor Neurological Disease
    Cutamesine (SA4503) dihydrochloride is a potent and selective sigma 1 receptor agonist with an IC50 of 17.4 nM in guinea pig brain membranes. Cutamesine dihydrochloride shows >100-fold less affinity for the sigma 2 receptor (IC50 of 1784 nM). Cutamesine dihydrochloride has antidepressant effects .
    Cutamesine dihydrochloride
  • HY-15084B
    Dizocilpine
    Maximum Cited Publications
    32 Publications Verification

    MK-801

    		 iGluR Neurological Disease
    Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux .
    Dizocilpine
  • HY-118140
    ZCZ011

    		Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    ZCZ011 is a potent and brain penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain .
    ZCZ011
  • HY-14136S
    Rimonabant-d10

    SR141716-d10

    		 Isotope-Labeled Compounds Cannabinoid Receptor Bacterial Infection Metabolic Disease Cancer
    Rimonabant-d10 is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
    Rimonabant-d10
  • HY-150407
    TSPO ligand-1

    		Ligands for Target Protein for PROTAC Autophagy Others Neurological Disease Cancer
    TSPO ligand-1 is the ligand of AUTAC4 (HY-134640) that can be used in the synthesis of PROTACs. TSPO ligand-1 is a mitochondrial outer membrane transmembrane structural domain protein can bind to AUTAC4 and regulate mitochondrial autophagy to promote targeted mitochondrial renewal. TSPO ligand-1 is also involved in the transport of cholesterol from the outer to inner mitochondrial membrane and serves as a sensitive biomarker of brain injury and neurodegeneration .
    TSPO ligand-1
  • HY-P10310A
    F9170 TFA

    		HIV Infection
    F9170 TFA is an amphipathic peptide with an activity of inactivate HIV-1 virions. F9170 TFA targets the conserved cytoplasmic tail of HIV-1 env and disrupts the integrity of the viral membrane. F9170 TFA is able to cross the blood-brain barrier (BBB) .
    F9170 TFA
  • HY-106469
    Taltrimide

    MY-117

    		 Drug Derivative Neurological Disease
    Taltrimide (MY-117), a lipophilic derivative of Taurine (HY-B0351), strongly inhibits the sodium-independent binding of Taurine to synaptic membranes of brain, the effects on the binding of GABA being less pronounced. Taltrimide exhibits definitive anticonvulsive effects in experimental epilepsy models .
    Taltrimide
  • HY-121810
    LBT-999

    		Dopamine Transporter Others
    LBT-999 is a phenyltropane derivative used for positron emission tomography (PET) exploration of the dopamine transporter (DAT). It has high affinity binding to DAT on rat striatal membranes and human postmortem brain slices in vitro, high uptake in the striatum in rat and baboon models in vivo, and its binding can be blocked by specific compounds.
    LBT-999
  • HY-10864
    URB-597
    5 Publications Verification

    KDS-4103

    		 FAAH Autophagy Mitophagy Neurological Disease
    URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .
    URB-597
  • HY-U00322
    5-HT3 antagonist 3

    		5-HT Receptor Neurological Disease
    5-HT3 antagonist 3 (Compound 15b) is a high-affinity 5-HT3 receptor antagonist. 5-HT3 antagonist 3 binds to 5-HT3 receptors in rat brain cortical membranes with Ki of 0.25 nM .
    5-HT3 antagonist 3
  • HY-100937R
    DPCPX (Standard)

    PD 116948 (Standard)

    		 Reference Standards Adenosine Receptor Cardiovascular Disease
    DPCPX (Standard) is the analytical standard of DPCPX. This product is intended for research and analytical applications. DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a Ki of 0.46 nM in 3H-CHA binding to A1 receptors in rat whole brain membranes .
    DPCPX (Standard)
  • HY-108483
    RP 67580

    		Neurokinin Receptor Neurological Disease Inflammation/Immunology
    RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation .
    RP 67580
  • HY-119033
    MGL-IN-1

    		MAGL Inflammation/Immunology
    MGL-IN-1 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor. MGL-IN-1 alleviates symptoms in a MS model in vivo and exhibits analgesic effects in an acute inflammatory pain model in vivo. MGL-IN-1 displays high membrane permeability and brain penetrant .
    MGL-IN-1
  • HY-131688
    2-Chlorohexadecanoic acid

    		PARP Caspase Inflammation/Immunology
    2-Chlorohexadecanoic acid, an inflammatory lipid mediator, interferes with protein palmitoylation,induces ER-stress markers, reduced the ER ATP content, and activates transcription and secretion of IL-6 as well as IL-8.2-Chlorohexadecanoic acid disrupts the mitochondrial membrane potential and induces procaspase-3 and PARP cleavage.2-Chlorohexadecanoic acid can across blood-brain barrier (BBB) and compromises ER- and mitochondrial functions in the human brain endothelial cell line hCMEC/D3 .
    2-Chlorohexadecanoic acid
  • HY-107855S
    DL-Mevalonolactone-d7

    (±)-Mevalonolactone-d7; Mevalolactone-d7

    		 Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .
    DL-Mevalonolactone-d7
  • HY-110016
    Docosatetraenylethanolamide

    DEA

    		 Endogenous Metabolite Cannabinoid Receptor Neurological Disease
    Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a Ki value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .
    Docosatetraenylethanolamide
  • HY-101654
    Rocepafant

    BN 50730; LAU-8080

    		 Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease Inflammation/Immunology
    Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research .
    Rocepafant
  • HY-107855S1
    DL-Mevalonolactone-d3

    (±)-Mevalonolactone-d3; Mevalolactone-d3

    		 Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone-d3 is the deuterium labeled DL-Mevalonolactone . DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .
    DL-Mevalonolactone-d3
  • HY-B0896
    Triacetin

    Glyceryl triacetate; 1,2,3-Triacetoxypropane

    		 Apoptosis HDAC Cancer
    Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .
    Triacetin
  • HY-19578A
    Isamoltan hydrochloride

    (±)-Isamoltane hydrochloride

    		 Adrenergic Receptor 5-HT Receptor Neurological Disease
    Isamoltan ((±)-Isamoltane) hydrochloride is a selective antagonist of 5-HT1B receptor, with an IC50 of 39 nM for inhibits the binding of [ 125I]ICYP to 5-HT1B recognition sites in rat brain membranes. Isamoltan hydrochloride is also a β-adrenoceptor ligand, with an IC50 of 8.4 nM. Isamoltan hydrochloride shows anxiolytic activity .
    Isamoltan hydrochloride
  • HY-P3138
    (Sar1)-Angiotensin II

    		Angiotensin Receptor Cardiovascular Disease
    (Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. (Sar1)-Angiotensin II binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-Angiotensin II can stimulate protein synthesis and cell growth in embryonic chick myocytes .
    (Sar1)-Angiotensin II
  • HY-111544
    EML741

    		Histone Methyltransferase Cancer
    EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC50 of 23 nM, Kd of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC50, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated .
    EML741

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: